Integration of Geriatric Measures Alongside Disease-Based Measures to Advance Precision Oncology for Older Veterans with Multiple Myeloma
Integration of Geriatric Measures Alongside Disease-Based Measures to Advance Precision Oncology for Older Veterans with Multiple Myeloma
批准号:
10426038
负责人:
Clark William DuMontier
金额:
$0.0万
依托单位国家:
美国
项目类别:
财政年份:
2020
资助国家:
美国
项目状态:
未结题
起止时间:
2020-10-01 至 2025-09-30
关键词:
AdoptedAgeAmerican Society of Clinical OncologyAttenuatedAwardChemotherapy-Oncologic ProcedureChronicChronic DiseaseClinicClinical InvestigatorCodeCollaborationsCommunicationCytogeneticsDataDatabasesDecision MakingDevelopmentDiagnosticDiseaseEffectivenessElderlyElectronic Health RecordFutureGeneticGenotypeGeriatric AssessmentGeriatricsGoalsHealthHealth systemHealthcareHospitalizationInformation CentersIntegrated Health Care SystemsInterdisciplinary StudyInvestigationK-Series Research Career ProgramsLeadershipMachine LearningMalignant NeoplasmsMassachusettsMeasuresMentorsMentorshipMissionModelingMultiple MyelomaNew EnglandOlder PopulationOncologistOncologyOutcomePatternPerformance StatusPhenotypePhysiologicalPrognosisRegimenResearchResearch PersonnelResearch TrainingResourcesRiskSeveritiesStatistical Data InterpretationSurvival RateTestingTimeToxic effectTrainingTraining ProgramsTranslatingTreatment ProtocolsTriplet Multiple BirthVeteransWorkage relatedbasebig-data sciencebody systemchemotherapyclinical centerclinical decision supportcohortcomparative effectivenessdata warehouseeducation researchelectronic dataepidemiology studyexperiencefrailtyhospitalization rateshuman old age (65+)indexinginnovationmortalitymultiple chronic conditionsolder patientoncology programpersonalized cancer therapypersonalized carepersonalized medicineprecision oncologypredictive modelingprognosticrisk stratificationroutine caresafety studyskillssociodemographic variablesstressorsupport toolssurvival predictiontooltumor
中文摘要
尽管主要的癌症关注组织,如美国临床学会
英文摘要
Although leading cancer-focused organizations such as the American Society of Clinical
Oncology now recommend geriatric assessments for all older adults with cancer, these
assessments have not been widely adopted within VA and elsewhere due to limitations in
resources, geriatrics expertise, and time in busy oncology clinics. The VA National Precision
Oncology Program is profiling tumor genetics in myeloma and other cancers to characterize
disease and personalize therapy in unprecedented fashion. However, truly personalized cancer
treatment for older Veterans must be based not only on tumor “genotype,” but also on older adult
“phenotype.” Dr. Clark DuMontier is a geriatrician and clinical investigator focused on integrating
geriatric measures into oncology. The research proposed for this CDA-2 will advance Dr.
DuMontier’s long-term goal of developing feasible and valid tools to help VA oncologists integrate
frailty and multimorbidity alongside myeloma-specific factors to advance precision oncology for
older Veterans with myeloma. The objectives of this application are to electronically measure
frailty and multimorbidity in over 5000 Veterans age ³ 65 years with myeloma newly treated in VA
from 2004-present using healthcare data that is readily available within VA’s nationally integrated
health system. Preliminary findings demonstrate that frailty and multimorbidity can be rapidly
assessed using diagnostic and procedural codes and data from the electronic health record
(EHR). Aim 1 will determine whether an electronic frailty index, the VA-FI, independently predicts
mortality and hospitalizations in older Veterans with myeloma, and whether it modifies the effect
of initial therapy on these outcomes. Analyses will include important myeloma-specific factors
such as triplet or doublet chemotherapy, stage and cytogenetics, sociodemographic variables,
and prognostic labs. Aim 2 will determine whether multimorbidity patterns independently predict
mortality and hospitalizations in myeloma, and whether they modify the effect of specific regimens
on these outcomes. A machine learning analysis will be applied to 67 chronic conditions
measured within the VA database to define these patterns and their impact in older Veterans with
myeloma. Aim 3 will develop and validate a predictive risk model for mortality that incorporates
frailty and multimorbidity with myeloma-specific factors. Once validated, this model will be
translated into a clinical decision support tool embedded in the VA EHR. This tool will help VA
oncologists to rapidly estimate frailty and multimorbidity and enhance individualized prognosis
and treatment decisions for older Veterans with myeloma. The mentored research and training
program described in this CDA-2 will accelerate Dr. DuMontier’s development into an independent
VA investigator in geriatric oncology. His mentorship team includes Drs. Jane Driver, Nikhil
Munshi, Michael Gaziano, and Mary Brophy—leaders in geriatrics, oncology, and big data science
from the New England Geriatric Research Education Clinical Center (GRECC), the
Massachusetts Veterans Epidemiology Research and Information Center (MAVERIC), and the
VA National Precision Oncology Program. Under the guidance of these mentors and in
collaboration with MAVERIC, Dr. DuMontier will pursue training that will provide (1) experience
with large database investigation; (2) expertise in advanced statistical analyses and machine
learning; (3) project management and multidisciplinary collaboration; and (4) communication,
leadership skills, and professional development. This training and mentored research will prepare
him to be competitive for a VA Merit Award toward independence as a VA clinician investigator.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Integration of Geriatric Measures Alongside Disease-Based Measures to Advance Precision Oncology for Older Veterans with Multiple Myeloma
-
批准号:10578715
-
项目类别:
-
资助金额:$0.0万
-
财政年份:2020
-
负责人:Clark William DuMontier
-
依托单位:
国内基金
海外基金
登录
查看更多内容
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
-
批准号:JCZRLH202601523
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
-
批准号:JCZRQN202500010
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:
-
依托单位:
对香豆酸抑制AGE-RAGE-Ang-1通路改善海马血管生成障碍发挥抗阿尔兹海默病作用
-
批准号:2025JJ70209
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2025
-
负责人:雷芬芳
-
依托单位:
AGE-RAGE通路调控慢性胰腺炎纤维化进程的作用及分子机制
-
批准号:--
-
项目类别:面上项目
-
资助金额:--
-
批准年份:2024
-
负责人:万荣
-
依托单位:
甜茶抑制AGE-RAGE通路增强突触可塑性改善小鼠抑郁样行为
-
批准号:2023JJ50274
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2023
-
负责人:贺志明
-
依托单位:
蒙药额尔敦-乌日勒基础方调控AGE-RAGE信号通路改善术后认知功能障碍研究
-
批准号:--
-
项目类别:地区科学基金项目
-
资助金额:33万元
-
批准年份:2022
-
负责人:都义日
-
依托单位:
补肾健脾祛瘀方调控AGE/RAGE信号通路在再生障碍性贫血骨髓间充质干细胞功能受损的作用与机制研究
-
批准号:--
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:叶宝东
-
依托单位:
LncRNA GAS5在2型糖尿病动脉粥样硬化中对AGE-RAGE 信号通路上相关基因的调控作用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2022
-
负责人:于海兵
-
依托单位:
围绕GLP1-Arginine-AGE/RAGE轴构建探针组学方法探索大柴胡汤异病同治的效应机制
-
批准号:81973577
-
项目类别:面上项目
-
资助金额:55.0万元
-
批准年份:2019
-
负责人:辛贵忠
-
依托单位:
AGE/RAGE通路microRNA编码基因多态性与2型糖尿病并发冠心病的关联研究
-
批准号:81602908
-
项目类别:青年科学基金项目
-
资助金额:18.0万元
-
批准年份:2016
-
负责人:刘括
-
依托单位: